Roswell
Park Cancer Institute has started a new, unique clinical trial
investigating immunotherapy for patients with advanced ovarian cancer.
Dr. Emese Zsiros, the study's Principal Investigator, explains the hope
behind combining pembrolizumab (Keytruda) with intravenous bevacizumab
(Avastin) and oral cyclophosphamide (Cytoxan).
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.